Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

This study has been completed.
Sponsor:
Information provided by:
ApoPharma
ClinicalTrials.gov Identifier:
NCT00530127
First received: September 13, 2007
Last updated: May 31, 2010
Last verified: May 2010

September 13, 2007
May 31, 2010
April 2008
July 2009   (final data collection date for primary outcome measure)
The patient's tolerance of treatment will be determined, as assessed by the occurrence of adverse events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
The patient's tolerance of treatment will be determined, as assessed by the occurrence of adverse events [ Time Frame: 6 months ]
Complete list of historical versions of study NCT00530127 on ClinicalTrials.gov Archive Site
The efficacy endpoints will be change in the score for 9-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW), Low-Contrast Letter Acuity test (LCLA), International Cooperative Ataxia Rating Scale (ICARS), and Friedreich's Ataxia Rating Scale (FARS). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
The efficacy endpoints will be change in the score for 9-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW), Low-Contrast Letter Acuity test (LCLA), International Cooperative Ataxia Rating Scale (ICARS), and Friedreich's Ataxia Rating Scale (FARS). [ Time Frame: 6 months ]
Not Provided
Not Provided
 
A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia
A Six-month Double-blind, Randomized, Placebo-controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

The primary objective of this study is to demonstrate the safety and tolerability of deferiprone in subjects with Friedreich's ataxia (FRDA).

The secondary objective is to evaluate the efficacy of deferiprone for the treatment of FRDA, as assessed by a 9-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW), Low-Contrast Letter Acuity test (LCLA), International Cooperative Ataxia Rating Scale (ICARS), and Friedreich's Ataxia Rating Scale (FARS).

The tertiary objectives are to evaluate the effect of deferiprone on:

  1. cardiac function as measured by changes in Left Ventricular Shortening Fraction (LVSF), Left Ventricular Ejection Fraction (LVEF) and Left Ventricular (LV) mass using echocardiogram (ECHO),
  2. quality of life using quality-of-life surveys, and
  3. functional status using Activities of Daily Living (ADL).

This will be a multi-centre, double-blind, randomized, placebo-controlled clinical trial. A total of 80 patients with Friedreich's ataxia will be enrolled. Eligible patients will receive deferiprone oral solution or placebo at a total daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day, divided into two-daily doses for 6 months.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Friedreich's Ataxia
  • Drug: placebo
    Same dose and frequency as treatment
  • Drug: deferiprone
    100 mg/mL
  • Drug: placebo
    Same dosage and frequency as study drug
  • Placebo Comparator: A
    Placebo solution
    Intervention: Drug: placebo
  • Experimental: B
    Deferiprone oral solution 20 mg/kg/day
    Intervention: Drug: deferiprone
  • Experimental: C
    Deferiprone oral solution 40 mg/kg/day
    Intervention: Drug: deferiprone
  • Placebo Comparator: D
    Placebo solution
    Intervention: Drug: placebo
  • Experimental: E
    deferiprone oral solution 60 mg/kg/day
    Intervention: Drug: deferiprone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosis of FRDA, with confirmed mutation (excludes point mutation) in the frataxin (FXN) gene and GAA repeats ≥ 400 on the shorter allele.
  2. Males or females aged 7 to 35 years.
  3. No exposure to idebenone, coenzyme Q10, vitamin C, vitamin E or other antioxidants as a supplement or as a drug therapy for a period of at least one month prior to start of treatment and during the study.
  4. Neurological testing: A FARS score >20 and <85 at Screening and Baseline.
  5. Female subjects of childbearing potential must have a negative pregnancy test at Baseline.
  6. If the subject is a heterosexual, sexually-active male, he confirms that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination.
  7. Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedule.

Exclusion Criteria:

  1. Iron deficiency defined as ferritin levels below the reference range for age- and sex-matched controls
  2. Unable to complete T25FW AND with score > 5 minutes in the 9HPT. (Subjects who can complete T25FW or with a score ≤ 5 minutes in the 9HPT will be allowed to enroll if the score has not doubled compared to screening).
  3. Abnormal ALT, greater than 2.0 times the upper limit of normal on two consecutive assessments.
  4. Serum creatinine outside the normal reference range.
  5. History or evidence of neutropenia defined by an absolute neutrophil count (ANC) < 1.5 x 109/L or thrombocytopenia defined by a platelet count <150 x 109/L.
  6. Refusal to participate in screening procedures or unable to participate in screening procedures or unable to comply with the requirements of the protocol.
  7. Receiving any investigational drug products or having received any investigational product within 30 days prior to enrollment into this study.
  8. Subjects who have previously taken deferiprone.
  9. Subjects who, in the opinion of the Investigator, represent poor medical, psychological or psychiatric risks, and for whom participation in an investigational trial would be unwise.
  10. Pregnant, breastfeeding or planning to become pregnant during the study period.
  11. History of malignancy.
  12. History of alcohol or drug abuse.
  13. Investigators, site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
  14. Hypersensitivity to the active substance (deferiprone) or any of the excipients in the oral solution.
  15. QT interval > 450 msec at Baseline.
Both
7 Years to 35 Years
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Canada,   France,   Italy,   Spain
 
NCT00530127
LA29-0207
Yes
Dian Shaw, ApoPharma Inc.
ApoPharma
Not Provided
Principal Investigator: Massimo Pandolfo, M.D. Hospital Erasme, Brussels, Belgium
Principal Investigator: Arnold Munnich, M.D. Hospital Necker-Enfants Malades, Paris, France
Principal Investigator: Franco Taroni Fondazione IRCCS Istituto Neurologico "C. Besta"
Principal Investigator: Martin Delatycki Murdoch Children's Research Institute, Vicotria, Australia
Principal Investigator: Javier Arpa La Fundaction Para la Investigacion Biomedica, Madrid, Spain
Principal Investigator: Mark Tarnopolsky, MD McMaster University
ApoPharma
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP